Vivos Therapeutics, a company focused on addressing the root causes of mild-to-moderate sleep apnea, announced Brad Amman has joined the company as Chief Financial Officer.
| DENVER, /PRNewswire/ -- Vivos Therapeutics, a company focused on addressing the root causes of mild-to-moderate sleep apnea, announced Brad Amman has joined the company as Chief Financial Officer. Mr. Amman will oversee the continued growth of Vivos Therapeutics and assist in achieving the company’s long-term strategic goals.
With over 20 years in the industry, Mr. Amman brings a wealth of experience at the financial helm of several public and private medical device, healthcare and biotech companies. Prior to joining Vivos Therapeutics Mr. Amman held executive leadership positions at CereScan and LifeVantage. Most recently, he served as CFO/COO at InLight Medical, which manufactures and distributes a polychromatic light therapy system. With his previous experience in the medical device field, Mr. Amman plans to broaden Vivos’ position in the marketplace. “His experience with other high growth public companies is of utmost value to our organization and his contributions are going to play a major role in shaping a bright future for Vivos,” said CEO Kirk Huntsman. “He joins us at an ideal time as we continue to streamline our operations, maintain discipline in capital deployment based on targeted returns, begin to generate free cash flow and optimize our balance sheet.” Mr. Amman holds an MBA from the University of Notre Dame and a Bachelor of Science in Accounting from the University of Denver. “I am delighted for the opportunity to bring my background, skills and leadership to help Vivos achieve great results for our people and shareholders,” said Mr. Amman. ABOUT VIVOS Media Contact:
SOURCE Vivos Therapeutics |
View original content to download multimedia:
